← Back to Search

Study Product, THC Product, Placebo for Motivation

N/A
Recruiting
Led By Noah Craft, MD
Research Sponsored by Phylos Bioscience, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights

Study Summary

Tetrahydrocannabivarin (THCV) is a rare cannabinoid and is a homologue of THC that differs only in the length of the alkyl side chain (3C vs 5C, respectively). Pre-clinical and clinical trials have shown that THCV has medical potential as a neuroprotectant, anti-inflammatory, anti-anxiety, and most notably as a therapeutic to improve glycemic control in type 2 diabetic patients. Several THCV products are available in states with recreational cannabis. Anecdotal reports from adult cannabis users indicate that THCV provides an energizing, focusing and euphoric high-while still creating a lucid, uplifting experience. Additionally, unlike THC-dominant products, THCV was not reported to increase appetite. Other anecdotal comments referring to increased ability to focus for long periods of time and being more active were common. Given anecdotal evidence, which shows that THCV is activating and improving focus, this provides rationale and justification to conduct a clinical research study to further test and understand whether THCV improves motivation, focus, level of energy, and does not stimulate appetite in healthy adults.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To observe the effect of various cannabinoid-containing products on motivation.
Secondary outcome measures
To observe the effect of cannabinoid products on motivation, energy level, focus, and appetite (MEFA).
Other outcome measures
To observe changes in overall symptoms and quality of life.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Study Product, THC Only Product, PlaceboExperimental Treatment1 Intervention
All study participants will receive and cross-over into each group: study product, thc-only product, and placebo groups. Study Product Ingredient List: Active Ingredients: 10mg THCV, 5mg THC Tapioca syrup, sugar, water, pectin, citric acid, natural flavors*, coconut oil, sodium citrate, cannabis extract, soy lecithin, Infused THC Gummy Ingredient List: Active Ingredients: 5mg THC Tapioca syrup, sugar, water, pectin, citric acid, natural flavors*, coconut oil, sodium citrate, cannabis extract, soy lecithin, THC. Non-infused Placebo Gummy Ingredient List: Tapioca syrup, sugar, water, pectin, citric acid, natural flavors*, coconut oil, sodium citrate, soy lecithin.

Find a Location

Who is running the clinical trial?

Phylos Bioscience, Inc.Lead Sponsor
People Science, Inc.Industry Sponsor
2 Previous Clinical Trials
230 Total Patients Enrolled
Noah Craft, MDPrincipal InvestigatorPeople Science, Inc.
1 Previous Clinical Trials
372 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What site did they apply to?
People Science, Inc.
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I am a healthy adult.im motivated to stay healthy and exercise. i need another source of income as well as be able to help others.
PatientReceived 2+ prior treatments
~35 spots leftby Apr 2025